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Backgroud 
Chronic infection with the hepatitis C virus (HCV) is a serious, progressive, and often 
life-threatening disease affecting an estimated 1.3 to 2.4 million people in Japan. It is 
estimated that approximately 15% to 30% of patients in Japan with chronic hepatitis C (CHC) 
will develop complications, including liver cirrhosis, hepatocellular carcinoma (HCC) and 
end-stage liver disease. In Japan, approximately 70% to 80% of infections are associated with 
Genotype (GT) 1 HCV and approximately 20% to 30% with GT2 HCV.  
For the treatment of GT1 CHC, pegylated interferon (PEG-IFN) and ribavirin (RBV) was 
long the standard of care in Japan. In 2011 and 2013, telaprevir (TVR) and simeprevir (SMV) 
in triple therapy with PEG-IFN and RBV were approved. The first IFN-free therapy was 
daclatasvir (DCV) with asunaprevir (ASV) approved in 2014. After DCV and ASV, the single 
tablet combination of ledipasvir (LDV) and sofosbuvir (SOF) has become available IFN-free 
treatment and was approved in 2015. For the treatment of GT2 CHC, the standard of care in 
many years was PEG-IFN and RBV. Recently in 2015, SOF has been approved in Japan for 
use in combination with RBV for the treatment of GT2 HCV as the first IFN-free regimen.    
Both LDV/SOF for GT1 and SOF+RBV for GT2 HCV treatment have shown higher SVR 
rates than previous IFN-based therapy in the clinical trials conducted in Japan, and offered 
important options for patients who are ineligible for IFN. However, LDV/SOF and SOF have 
much higher treatment costs than other treatment options. Therefore, from the perspective of 
healthcare decision makers, cost-effectiveness data is needed to assess whether additional 
expenditures for LDV/SOF and SOF would result in additional clinical benefit. 
 
Objective 
     The objective of this study is to assess the cost-effectiveness of LDV/SOF for GT1 
CHC and SOF+RBV for GT2 CHC treatment in Japan, using a markov state transition model 
and the cost and outcome data generated from Japan.  
 
Methods and results 
1) Adjustment of the Cure model and the validation of the adjusted model 
     The Cure model was developed from the model that was used in UK for NICE, and has 
been used in a published cost-effectiveness study for sofosbuvir in the treatment of CHC. The 
Cure model included 9 relevant health states (non-cirrhotic, cirrhotic, non-cirrhotic SVR, 
cirrhotic SVR, HCC, etc.) 
     The Cure model was adjusted for the cost-effectiveness study in Japan by replacing the 
transition probabilities mainly reported from Japanese clinical literature. Annual mortality 
rates were obtained from the Statistics Department of the Ministry of Health, Labour and 
Welfare. Cost and outcomes were discounted at 2%. 
     The validity of the adjusted model was evaluated by the comparision of survival rates 
and HCC incidence rates from model estimations and epidemiological literature. 
 
2) Target population & treatment options 
  For GT1 HCV, four patient subgroups were considered: a) treatment-naïve (TN) 
non-cirrhotic, b) TN cirrhotic, c) Treatment-experienced (TE) non-cirrhotic, d) TE cirrhotic. 
 
	
  For GT2 HCV, four patient subgroups were considered: a) TN interferon eligible (IE), b) 
TN unsuitable for interferon (UI), 3) TE IE, 4) TE UI. For each subgroup, the proportion of 
patients initiating treatment at the non-cirrhotic stage was set to 82%. 
  Treatment options as comparators were selected based on the most recent HCV treatment 
guidelines for Japan.  
 
3) Efficacy, utility and costs data 
  SVR rates of different therapies from Japanese and international clinical trials were used in 
the model. Utilities related to each health state and the utility changes related to antivirus 
treatments were obtained from Japanese studies.  
  Drug costs were derived from the 2015 National Drug Tariff. No treatment-related adverse 
events costs were included in this analysis due to data scarcity. Hospitalization costs and 
monitoring costs during the treatment, costs related with each health state were estimated 
based on published Japanese literature. Indirect costs, including productivity losses in terms 
of absenteeism and presenteeism, were also included in scenario analysis. 
 
5) Model outcomes 
  The primary outcome measure was quality-adjusted life years (QALYs) gained. Life years 
(LYs) gained was a secondary outcome. Incremental cost-effectiveness ratio (ICER) per 
QALY and per LY was calculated. 
 
6) Sensitivity analyses 
  Both a deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA) 
were conducted.  
 
7) Budget impact analyses 
   The weight and patient number of each subgroup of GT1 and 2 CHC was estimated. The 
additional costs invested for LDV/SOF and SOF+RBV treatments, and the additional total 
direct costs compared with other treatments in each subgroup from the model analysis were 
used to multiply the patient number, to calculate the total budget impact of introducing 
LDV/SOF and SOF+RBV. Moreover, the comparators, patient numbers, and other parameters 
were varied to conduct scenario analyses for the budget impact analyses. 
 
Results 
1) Validity of the adjusted model  
  The adjusted model was developed and its validity has been confirmed. Between model 
estimations and literature reported data, the absolute differences in survival rates (5~15 
years) were 2.4%~5.8%, while the absolute differences in HCC incidence rates (5~15 
years) were 1%~5.6%.  
 
2) Cost-utility of LDV/SOF for the treatment of GT1 CHC 
  LDV/SOF was found to have improved all the health related outcomes in all the patient 
subgroups, including QALYs, LYs, and the incidence of HCC and DCC, compared with 
other treatment options (PEGIFN+RBV, SMV+PEGIFN+RBV, TVR+ PEGIFN+RBV, 
 
	
DCV+ASV, No treatment). The ICER (JPY/QALY) of LDV/SOF compared with 
SMV+PEGIFN+RBV in TN non-cirrhotic subgroup was calculated as: 6,097,686. In other 
three subgroups compared with DCV+ASV, the ICER (JPY/QALY) of LDV/SOF was 
caluculated as 2,853,483 (TN, cirrhotic), 2,015,836 (TE, non-cirrhotic), 1,553,448 (TE, 
cirrhotic). The robustness of the analysis results has been shown in DSA and PSA. 
   The additional costs invested for treatment, and the additional total direct costs of 
introducing LDV/SOF were estimated to be 2.89 and 2.37 trillion JPY. 
 
3) Cost-utility of LDV/SOF for the treatment of GT1 CHC 
    SOF+RBV was found to have improved all the health related outcomes in all the 
patient subgroups, including QALYs, LYs, and the incidence of HCC and DCC, 
compared with other treatment options (PEGIFN+RBV, TVR+PEGIFN+RBV, No 
treatment). The ICER (JPY/QALY) of SOF+RBV compared with PEGIFN+RBV in TN, 
IE subgroup and TE, IE was calculated as: 2,148,465 and 494,049, respectively. In TN, 
UI and TE, UI subgroup, SOF+RBV was dominant compared with no treatment (less 
costs, more effective). The ICER (JPY/QALY) of LDV/SOF compared with 
TVR+PEGIFN+RBV in TE, IE, and non-cirrhotic subgroup was caluculated as 3,540,914. 
The robustness of the analysis results has been shown in DSA and PSA. 
      The additional costs invested for treatment, and the additional total direct costs of 
introducing SOF+RBV were estimated to be 1.38 and 0.14 trillion JPY. 
 
Conclusion 
    Both LDV/SOF for GT1 and SOF+RBV for GT2 HCV treatment were considered to be 
cost-effective options in Japan against other treatments. Moreover, the interferon-free nature 
of LDV/SOF and SOF+RBV has a key advantage in terms of better treatment tolerability, 
fewer adverse events and shorter treatment duration. 
   The evidence generated from this research provided more support for the rational 
decision-making on the drug prices and health insurance strategies in this field in future. 
 
